Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals has reported Non Operating Income for 10 years, with the latest figure at -$58.8 million in Q2 2026.

• On a quarterly basis, Non Operating Income rose 1.48% year-over-year to -$58.8 million in Q2 2026; TTM through Jun 2026 was -$252.7 million, a 11.94% increase from a year earlier, with the FY2025 full-year figure at -$254.9 million, up 16.25% from the prior year.
• Non Operating Income was -$58.8 million for Q2 2026 at Amneal Pharmaceuticals, up from -$61.6 million in the prior quarter.
• The five-year high for Non Operating Income was -$33.2 million in Q1 2022, with the low at -$97.7 million in Q4 2023.
• Average Non Operating Income over 5 years is -$59.9 million, with a median of -$59.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income tumbled 123.53% in 2023, then jumped 37.66% in 2025.
• Over 5 years, Non Operating Income stood at -$43.7 million in 2022, then sank by 123.53% to -$97.7 million in 2023, then grew by 6.7% to -$91.1 million in 2024, then jumped by 37.66% to -$56.8 million in 2025, then decreased by 3.49% to -$58.8 million in 2026.
• The last three Non Operating Income figures came in at -$58.8 million (Q2 2026), -$61.6 million (Q1 2026), and -$56.8 million (Q4 2025), per Business Quant data.